Pharmaceutical industry groups say they support the US Food and Drug Administration's (FDA) draft guidance on new approach ...

The U.S. Food and Drug Administration today issued a draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs. “This draft guidance not only ...

Please provide your email address to receive an email when new articles are posted on . The FDA announced plans in 2025 to reduce animal testing requirements in biomedical research. New approach ...

Based Models is calling for greater flexibilty from the FDA to accomodate rapidly changing technologies like stem ...

The past year has marked a turning point for New Approach Methodologies (NAMs) in preclinical drug development. No longer experimental curiosities, these human-relevant approaches have rapidly gained ...

As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven platforms, ...

Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But ...

To stay on forefront of research, UL should move away from animal testing, argues guest columnist Jennifer Riedl Cross ...

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ZURICH/SCHLIEREN, Switzerland, December 24, 2025 – DiNABIOS AG, ...

The Trump administration is redoubling its efforts to phase out animal testing in drug development and seeking to develop new biotechnology methods instead to spur innovation in the pharmaceutical ...